These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 6277474)
1. Collateral sensitivity of 6-mercaptopurine-resistant sublines of P388 and L1210 leukemia to the new purine antagonists, 5-carbamoyl-1H-imidazol-4-yl piperonylate and 4-carbamoylimidazolium 5-olate. Inaba M; Fukui M; Yoshida N; Tsukagoshi S; Sakurai Y Cancer Res; 1982 Mar; 42(3):1103-6. PubMed ID: 6277474 [TBL] [Abstract][Full Text] [Related]
2. New antitumor imidazole derivative, 5-carbamoyl-1H-imidazol-4-yl piperonylate, as an inhibitor of purine synthesis and its activation by adenine phosphoribosyltransferase. Fukui M; Inaba M; Tsukagoshi S; Sakurai Y Cancer Res; 1982 Mar; 42(3):1098-102. PubMed ID: 6120758 [TBL] [Abstract][Full Text] [Related]
3. Selective reduction of intracellular guanosine 5'-triphosphate pool by 4-carbamoylimidazolium 5-olate in murine tumor cells. Fukui M; Inaba M; Tsukagoshi S; Sakurai Y Cancer Res; 1986 Jan; 46(1):43-6. PubMed ID: 2866032 [TBL] [Abstract][Full Text] [Related]
4. Collateral sensitivity to N-(phosphonacetyl)-L-aspartic acid in a line of P388 leukemia cells selected for resistance to L-(alpha S, 5S)-alpha-amino-3- chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin). Ardalan B; Jayaram HN; Johnson RK Cancer Res; 1983 Apr; 43(4):1598-601. PubMed ID: 6831405 [TBL] [Abstract][Full Text] [Related]
5. Antitumor activities of newly synthesized 5-carbamoyl-1 H-imidazol-4yl 1-adamantanecarboxylate and 5-carbamoyl-1H-imidazol-4yl piperonylate. Yoshida N; Kiyohara T; Fukui M; Atsumi T; Ogino S; Inaba M; Tsukagoshi S; Sakurai Y Cancer Res; 1980 Oct; 40(10):3810-4. PubMed ID: 7438064 [TBL] [Abstract][Full Text] [Related]
6. The effects of 6-mercaptopurine nucleotide derivatives on the growth and survival of 6-mercaptopurine-sensitive and -resistant cell culture lines. Johnston HP; Hawley P; White SE; Gibson I; Tidd DM Br J Cancer; 1985 Apr; 51(4):505-14. PubMed ID: 3838480 [TBL] [Abstract][Full Text] [Related]
7. Optimal treatment schedule and antitumor spectrum of 4-carbamoylimidazolium 5-olate (SM-108) in murine tumors. Yoshida N; Nakamura M; Fukui M; Morisada S; Ogino S; Inaba M; Tsukagoshi S; Sakurai Y Cancer Res; 1983 Dec; 43(12 Pt 1):5851-6. PubMed ID: 6640536 [TBL] [Abstract][Full Text] [Related]
8. 6-Mercaptopurine-induced potentiation of active immunotherapy in L1210-bearing mice treated with concanavalin A-bound leukemia cell vaccine. Kataoka T; Akahori Y; Sakurai Y Cancer Res; 1984 Feb; 44(2):519-24. PubMed ID: 6537896 [TBL] [Abstract][Full Text] [Related]
9. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice. Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799 [TBL] [Abstract][Full Text] [Related]
10. Adenine phosphoribosyltransferase deficiency in cultured mouse mammary tumor FM3A cells resistant to 4-carbamoylimidazolium 5-olate. Koyama H; Kodama H Cancer Res; 1982 Oct; 42(10):4210-4. PubMed ID: 7105014 [TBL] [Abstract][Full Text] [Related]
11. Basis of observed resistance of L1210 leukemia in mice: methotrexate, 6-thioguanine, 6-methylmercaptopurine riboside, 6-mercaptopurine, 5-fluorouracil, and 1-beta-D-arabinofuranosylcytosine administered in different combinations. Kim K; Blechman WJ; Riddle VG; Pardee AB Cancer Res; 1981 Nov; 41(11 Pt 1):4529-34. PubMed ID: 7198006 [TBL] [Abstract][Full Text] [Related]
12. Effects of nucleoside transport inhibitors on the salvage and toxicity of adenosine and deoxyadenosine in L1210 and P388 mouse leukemia cells. Plagemann PG; Wohlhueter RM Cancer Res; 1985 Dec; 45(12 Pt 1):6418-24. PubMed ID: 3877568 [TBL] [Abstract][Full Text] [Related]
13. [Cross-resistance of HO-221 and various antitumor agents in sublines of mouse leukemia]. Nakajima T; Masuda H; Okamoto T; Watanabe M; Yokoyama K; Yamada N; Fujimoto S; Tsukagoshi S; Taguchi T Gan To Kagaku Ryoho; 1991 Feb; 18(2):201-9. PubMed ID: 1899547 [TBL] [Abstract][Full Text] [Related]
14. Restoration of sensitivity to oxazaphosphorines by inhibitors of aldehyde dehydrogenase activity in cultured oxazaphosphorine-resistant L1210 and cross-linking agent-resistant P388 cell lines. Sladek NE; Landkamer GJ Cancer Res; 1985 Apr; 45(4):1549-55. PubMed ID: 3978623 [TBL] [Abstract][Full Text] [Related]
15. [Antitumor activities of orally administered 4-carbamoylimidazolium-5-olate (SM-108)]. Nakamura M; Fukui M; Morisada S; Inaba M; Tsukagoshi S; Sakurai Y Gan To Kagaku Ryoho; 1985 Oct; 12(10):2030-6. PubMed ID: 4051519 [TBL] [Abstract][Full Text] [Related]
16. Resistance to purine and pyrimidine nucleoside and nucleobase analogs by the human MDR1 transfected murine leukemia cell line L1210/VMDRC.06. Zeng H; Lin ZP; Sartorelli AC Biochem Pharmacol; 2004 Sep; 68(5):911-21. PubMed ID: 15294454 [TBL] [Abstract][Full Text] [Related]
17. Characterization of four drug-resistant P388 sublines: resistance/sensitivity in vivo, resistance-and proliferation-markers, immunogenicity. Fichtner I; Stein U; Hoffmann J; Winterfeld G; Pfeil D; Hentschel M Anticancer Res; 1994; 14(5A):1995-2003. PubMed ID: 7847840 [TBL] [Abstract][Full Text] [Related]
18. Collateral sensitivity to cross-linking agents exhibited by cultured L1210 cells resistant to oxazaphosphorines. Sladek NE; Low JE; Landkamer GJ Cancer Res; 1985 Feb; 45(2):625-9. PubMed ID: 3967238 [TBL] [Abstract][Full Text] [Related]
19. Biochemical characteristics of a 5-fluorouracil-resistant subline of P388 leukemia. Tezuka M; Sugiyama H; Tamemasa O; Inaba M Gan; 1982 Feb; 73(1):70-6. PubMed ID: 7117749 [TBL] [Abstract][Full Text] [Related]